Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 8 (6) |
| Completed vs Stopped Early | 2 / 4 (26.7%) |
| Median Closed Actual Enrollment | 63 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06753916 | ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Massachusetts Eye and Ear Infirmary Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.